Takeda Pharmaceutical Co., Ltd./ JP3463000004 /
| 11/7/2024 3:30:00 PM | Chg. - | Volume | Bid- | Ask- | Market Capitalization | Dividend Y. | P/E Ratio |
|---|---|---|---|---|---|---|---|
| 26.7600USD | - | 119,689 Turnover: 7,599.8400 |
-Bid Size: - | -Ask Size: - | 43.41 bill.USD | - | - |
Assets
| 2019 - in mill. JPY |
2020 IFRS in mill. JPY |
2021 IFRS in mill. JPY |
2022 IFRS in mill. JPY |
2023 IFRS in mill. JPY |
|||||||
|---|---|---|---|---|---|---|---|---|---|---|---|
| Property and Equipment | 1.32 mill. | 1.39 mill. | 1.45 mill. | 1.58 mill. | 1.69 mill. | ||||||
| Intangible Assets | 4.86 mill. | 4.17 mill. | 3.91 mill. | 3.82 mill. | 4.27 mill. | ||||||
| Long-Term Investments | 114,658 | 262,121 | 235,882 | 96,579 | 99,174 | ||||||
| Fixed Assets | - | - | - | 10.58 mill. | 11.56 mill. | ||||||
| Inventories | 986,744 | 759,599 | 753,881 | 853,167 | 986,457 | ||||||
| Accounts Receivable | 741,907 | 757,005 | 783,091 | 696,644 | 649,429 | ||||||
| Cash and Cash Equivalents | 702,093 | 637,614 | 966,222 | 849,695 | 533,530 | ||||||
| Current Assets | 3.05 mill. | 2.47 mill. | 2.71 mill. | 2.59 mill. | 2.4 mill. | ||||||
| Total Assets | 13.87 mill. | 12.82 mill. | 12.91 mill. | 13.18 mill. | 13.96 mill. | ||||||
Liabilities
| 2019 - in mill. JPY |
2020 IFRS in mill. JPY |
2021 IFRS in mill. JPY |
2022 IFRS in mill. JPY |
2023 IFRS in mill. JPY |
|||||||
|---|---|---|---|---|---|---|---|---|---|---|---|
| Accounts Payable | 327,394 | 318,816 | 343,838 | 516,297 | 649,233 | ||||||
| Long-term debt | - | - | - | 4.14 mill. | 4.04 mill. | ||||||
| Liabilities to Banks | 984,946 | 586,817 | 22,153 | - | - | ||||||
| Provisions | 1.02 mill. | 930,490 | 726,803 | 947,212 | 834,949 | ||||||
| Liabilities | 8.71 mill. | 8.09 mill. | 7.74 mill. | 7.49 mill. | 7.6 mill. | ||||||
| Share Capital | 1.64 mill. | 1.67 mill. | 1.67 mill. | - | - | ||||||
| Total Equity | 5.16 mill. | 4.73 mill. | 5.18 mill. | 5.68 mill. | 6.35 mill. | ||||||
| Minority Interests | 4,006 | 4,003 | 4,140 | 504 | 549 | ||||||
| Total liabilities equity | 13.87 mill. | 12.82 mill. | 12.91 mill. | 13.18 mill. | 13.96 mill. | ||||||
Income Statement
| 2019 - in mill. JPY |
2020 IFRS in mill. JPY |
2021 IFRS in mill. JPY |
2022 IFRS in mill. JPY |
2023 IFRS in mill. JPY |
|||||||
|---|---|---|---|---|---|---|---|---|---|---|---|
| Revenues | 2.1 mill. | 3.29 mill. | 3.2 mill. | 3.57 mill. | 4.03 mill. | ||||||
| Depreciation (total) | 203,372 | 455,420 | 421,864 | 472,915 | 542,443 | ||||||
| Operating Result | 204,969 | 100,408 | 509,269 | 460,844 | 490,505 | ||||||
| Interest Income | -66,446 | -137,175 | -143,110 | -142,907 | -106,785 | ||||||
| Income Before Taxes | 94,896 | -60,754 | 366,235 | - | - | ||||||
| Income Taxes | -14,118 | -105,044 | -9,936 | 72,405 | 58,052 | ||||||
| Minority Interests Profit | 112 | -49 | -166 | -107 | -21 | ||||||
| Net Income | 109,126 | 44,241 | 376,005 | 230,059 | 317,017 | ||||||
Per Share
Cash Flow
| 2019 - in mill. JPY |
2020 IFRS in mill. JPY |
2021 IFRS in mill. JPY |
2022 IFRS in mill. JPY |
2023 IFRS in mill. JPY |
|||||||
|---|---|---|---|---|---|---|---|---|---|---|---|
| Cash Flow from Operating Activities | 328,479 | 669,752 | 1.01 mill. | 1.12 mill. | 977,156 | ||||||
| Cash Flow from Investing Activities | -2.84 mill. | 292,119 | 393,530 | -198,125 | -607,102 | ||||||
| Cash Flow from Financing | 2.95 mill. | -1.01 mill. | -1.09 mill. | -1.07 mill. | -709,148 | ||||||
| Decrease / Increase in Cash | 439,018 | -43,342 | 316,107 | - | - | ||||||
| Employees | 49,578 | 47,495 | 47,099 | 47,000 | 47,347 | ||||||
